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The selective vasopressin V2–receptor antagonist tolvaptan is
eliminated almost exclusively by non-renal mechanisms. As
renal impairment can influence the pharmacokinetics of
drugs even when eliminated by non-renal mechanisms,
we evaluated the effect of renal insufficiency on the
pharmacokinetics/pharmacodynamics of tolvaptan.
Thirty-seven patients were grouped by a 24-h creatinine
clearance (CrCL) and evaluated for 48h after a single 60mg
oral dose in the fasting state. Mean tolvaptan exposure was
90% higher in the under 30-ml/min group compared with the
over 60-ml/min group with individual values significantly but
negatively correlated with increasing baseline CrCL. There
was a greater and more rapid increase in urine output and
free water clearance in the over 60-ml/min compared with
the renal impaired groups, but they returned to baseline
more quickly. Serum sodium increased more rapidly in the
over 60 as opposed to the under 30-ml/min group, but
overall maximum increases were similar across groups. Small
decreases in mean CrCL and small increases in mean serum
creatinine/potassium were independent of baseline CrCL. The
percent fractional free water clearance with respect to CrCL
was significantly but negatively correlated with increasing
baseline CrCL. No unexpected adverse events were reported.
Thus, renal impairment attenuated the increase in 24-h urine
volume and free water clearance caused by tolvaptan,
consistent with decreased nephron function in renal
impairment. The delay in serum sodium increase was
consistent with the longer duration needed to excrete
sufficient water to cause the increase.
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Tolvaptan is an orally active vasopressin V2–receptor anta-
gonist, which is approved for treatment of specific forms of
hyponatremia in the United States and Europe.1–3 The
recommended starting dose for hyponatremia is 15mg
once daily, which can be titrated to a maximum of 60mg
once daily, as needed, to raise serum sodium.4 Tolvaptan is
also used in clinical testing in subjects with autosomal
dominant polycystic kidney disease.5–8
The pharmacokinetics and pharmacodynamics of tolvap-
tan have been evaluated in multiple trials in healthy subjects.
Dose-proportional increases in exposure to tolvaptan, as
measured by area under the curve to infinity (AUCN) and
maximum plasma concentration (Cmax), were observed for
doses of 15–60mg.9–11 After oral administration, tolvaptan
produced aquaresis characterized by increases in urine
volume and free water clearance (FWC), and consequent
increases in serum osmolality and serum sodium within the
24-h period after dosing.10 These effects were not accom-
panied by significant changes in serum potassium, creatinine
clearance (CrCL), or urine electrolyte excretion. A recently
published trial showed that the pharmacokinetics and
pharmacodynamics of tolvaptan 30mg were not clinically
significantly affected by race or by administration with
food.12
Tolvaptan is eliminated almost exclusively by non-renal
routes, witho1% of the administered dose excreted unchanged
in urine.10 Renal impairment can, however, influence
the pharmacokinetics of drugs predominantly eliminated by
non-renal mechanisms through effects on drug metabolism
enzymes and the activities of drug transporters.13 Therefore,
the present trial investigated whether renal impairment
influences the pharmacokinetics and pharmacodynamics
of tolvaptan following administration of a single 60-mg
oral dose.
RESULTS
Subject disposition and characteristics
Thirty-seven subjects were enrolled and given a single
60-mg dose of tolvaptan, including 12 subjects with CrCL
o30ml/min, 12 subjects with CrCL of 30–60ml/min, and 13
subjects with CrCL 460ml/min. All subjects completed the
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trial as planned. The demographics of the CrCL o30- and
460-ml/min groups were well balanced, consistent with the
protocol-specified matching of these groups by age, weight,
and sex (Table 1). In comparison, the CrCL 30- to 60-ml/min
group had a higher mean age, fewer women, and more
Hispanic/Latino subjects than the other groups. The mean
CrCL values in the CrCLo30-, 30- to 60-, and460-ml/min
groups were 20.6, 49.6, and 95.8ml/min, respectively. As
expected, higher mean cystatin C concentrations were seen in
subjects with greater degrees of renal impairment. One subject
in the CrCL460-ml/min group had diabetes and was taking
daily medication in violation of the eligibility criteria. This
subject was excluded from the pharmacokinetic and pharma-
codynamic analyses but was included in the safety analysis.
Pharmacokinetics
Tolvaptan plasma concentrations reached maximal levels by
2–3 h after dosing and then decreased in an exponential
manner (Figure 1). Subjects with renal impairment (CrCL
o30 and 30–60ml/min) had slightly higher plasma concen-
trations than those with preserved renal function (CrCL
460ml/min) throughout most of the 48-h evaluation
period. When measured by AUCN, exposure to tolvaptan,
on average, was 90% higher in the CrCLo30-ml/min group
and 83% higher in the CrCL 30- to 60-ml/min group than in
the CrCL 460-ml/min group (Table 2). Mean Cmax values
were somewhat higher and mean values for clearance (CL/F)
were lower in the groups with renal impairment than in the
preserved renal function group. Individual AUCN values
were negatively correlated with increasing baseline CrCL
(r2¼ 0.132; P¼ 0.028) (Figure 2). Individual Cmax values
showed a trend for being negatively correlated with baseline
CrCL (P¼ 0.087), whereas CL/F showed a trend for being
positively correlated with baseline CrCL (P¼ 0.059). Neither
terminal-phase elimination half-life nor percent fraction of
unbound drug (%fu) was correlated with baseline CrCL.
Pharmacodynamics
The onset of tolvaptan action was rapid as FWC was
increased in all subjects in the 0- to 4-h urine collection
period. The CrCL 460-ml/min group had larger and more
rapid increases in urine excretion rate and FWC after
tolvaptan administration, and these parameters returned to
baseline more quickly (ie, within 24 h) than in the groups
with renal impairment (Figure 3).
Table 1 |Demographic and clinical characteristics
Parametera
CrCL o30ml/
min (n¼ 12)
CrCL 30–60ml/
min (n¼ 12)
CrCL 460ml/
min (n¼ 13)
Age (year) 58.3 (11.2) 70.0 (8.2) 58.8 (11.4)
Sex (n (%))
Male 7 (58.3) 10 (83.3) 8 (61.5)
Female 5 (41.7) 2 (16.7) 5 (38.5)
Race (n (%))
White 10 (83.3) 11 (91.7) 13 (100)
Black 2 (16.7) 1 (8.3) 0 (0)
Ethnicity (n (%))
Hispanic/Latino 5 (41.7) 10 (83.3) 5 (38.5)
Non-Hispanic/
Latino
7 (58.3) 2 (16.7) 8 (61.5)
Weight (kg) 76.5 (15.1) 71.9 (11.5) 76.3 (11.5)
Height (cm) 170.3 (7.7) 165.5 (8.5) 173.2 (9.9)
BMI (kg/m2) 26.4 (5.3) 26.1 (2.5) 25.4 (3.3)
CrCL (ml/min) 20.6 (6.4) 49.6 (7.3) 95.8 (17.5)
Serum sodium
(mmol/l)
138.8 (3.2) 140.3 (2.5) 140.5 (1.4)
Serum osmolality
(mOsm/kg)
315.1 (11.4) 297.7 (8.6) 292.6 (3.6)
Serum creatinine
(mg/dl)
3.5 (1.0) 1.5 (0.3) 0.9 (0.2)
Cystatin C (mg/l) 3.4 (0.7) 1.3 (0.3) 0.9 (0.3)
Abbreviations: BMI, body mass index; CrCL, creatinine clearance.
aAll values presented as mean (±s.d.), unless otherwise specified.
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Figure 1 |Mean (±s.d.) tolvaptan plasma concentration–time
profiles by creatinine clearance.
Table 2 | Pharmacokinetic parameters for tolvaptan by CrCL
group
Parametera
CrCL o30
ml/min (N¼ 12)
CrCL 30–60
ml/min (N¼ 12)
CrCL 460
ml/min (N¼ 12)
Total tolvaptan
Cmax (ng/ml) 535 (183) 621 (241) 417 (150)
tmax (h) 3.5 (2.0–6.0) 3.0 (2.0–4.0) 2.0 (1.0–4.0)
AUCt (ngh/ml) 6690 (3550) 6470 (3090) 3530 (1570)
t1/2,z (h)
b 9.1 (2.8) 9.2 (3.3) 10.1 (8.3)
AUCN (ngh/ml)
b 7360 (3580) 6980 (3360) 3890 (1910)
CL/F (ml/min/kg)b 2.65 (2.40) 2.37 (0.80) 4.55 (2.58)
Unbound tolvaptan
fu (%) 1.2 (0.8) 0.6 (0.1) 1.0 (0.3)
Cmax,u (ng/ml) 5.89 (2.74) 3.35 (0.85) 4.29 (1.92)
AUCN,u (ngh/ml)
b 71.8 (37.4) 36.4 (11.9) 37.5 (21.2)
CL/Fu (ml/min/kg)
b 0.034 (0.038) 0.014 (0.006) 0.049 (0.036)
Abbreviations: AUCt, area under the curve from time zero to the last sampling
time; AUCN, AUC to infinity; CL/F, clearance; Cmax, maximum plasma concentration;
CrCL, creatinine clearance; fu, fraction of unbound drug; tmax, time to Cmax; t1/2,z,
terminal half-life; u, unbound.
aAll values are mean (±s.d.), except for tmax, which is shown as median (range).
bn¼ 11 per group.
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Mean fluid balances were negative for all groups on day 1.
The subjects with CrCL460ml/min had greater increases in
fluid intake in the 24-h period after tolvaptan administration
such that mean fluid balance was similar to that in the CrCL
30- to 60-ml/min group (Figure 4). Fluid intake remained
marginally higher on day 2 across all groups, but mean
fluid balance remained negative in the CrCL 30- to 60- and
o30-ml/min groups, consistent with the increased FWC on
day 2 (Table 3).
In the first 24 h after dosing, tolvaptan reduced mean
CrCL by 4–7% in subjects with renal impairment, but did not
change mean CrCL in the group with preserved renal
function (Figure 5). On day 2, mean CrCL was reduced
across all groups, ranging from 4% in the group with
preserved renal function to 11% in the group with CrCL
30–60ml/min. These mean changes were not significant,
given the large intersubject variability in CrCL change.
Moreover, percent changes in CrCL following tolvaptan were
not correlated with baseline CrCL (Figure 6).
The percent change from baseline in fractional FWC with
respect to CrCL (FWC/CrCL) for the 0- to 24-h period was
negatively correlated with baseline CrCL (r2¼ 0.144;
P¼ 0.022); mean (standard deviation (s.d.)) values for the
CrCL o30-, 30- to 60-, and 460-ml/min groups were 4.1%
(2.3%), 3.5% (1.5%), and 2.5% (0.9%), respectively.
Tolvaptan increased serum osmolality and sodium more
rapidly in subjects with CrCL 460 or 30–60ml/min than in
those with CrCL o30ml/min (Figure 7). However, the
serum sodium increases observed from 12 to 48 h after
dosing were similar in magnitude, regardless of baseline
CrCL (Table 4). Serum potassium concentrations increased
minimally after tolvaptan administration: mean changes
from baseline were B0.1–0.2mEq/l and were independent
of CrCL. Mean serum creatinine increased byB0.1–0.3mg/dl
after tolvaptan administration and also were independent of
baseline CrCL.
Subjects with CrCL 460ml/min had increases in mean
urinary excretion of osmoles, sodium, and potassium in the
24-h interval after tolvaptan administration, which was not
seen in subjects with CrCL o30 or 30–60ml/min (Figure 8).
The increased excretion appeared to occur when FWC was
43ml/min.
Pharmacokinetic/pharmacodynamic relationships
Tolvaptan plasma concentrations, as represented by Cmax or
AUCN, after the single 60-mg dose were not correlated with
changes in any of the pharmacodynamic end points.
Although Cmax and AUCN were higher in subjects with
poorer renal function, the pharmacodynamic responses of
increased urine output and FWC were not associated with
tolvaptan concentrations and were instead associated with
baseline CrCL, thereby reflecting the amount of kidney
function still present. The percent changes in CrCL were
similar across the range of baseline CrCL values (Figure 6).
Safety
Following treatment with a single 60-mg dose of tolvaptan,
there were no unexpected treatment-emergent adverse events
(TEAEs). Twenty-six subjects (70%) had TEAEs, and all were
mild or moderate in severity. The most common TEAEs were
thirst (overall 27%; range across groups 23–33%), pollakiuria
(24%; 8–33%), and dry mouth (14%; 8–25%). There were no
clinically meaningful changes in vital signs or electrocardio-
graphic parameters. Ten subjects (27%) had potentially
clinically significant abnormalities in laboratory test values,
including five with CrCL o30ml/min and four with CrCL
30–60ml/min. The most common of these abnormalities
were elevated glucose, urea nitrogen, calcium, uric acid, and
decreased hemoglobin. Hyperglycemia and hypoglycemia
were reported as TEAEs by two subjects each, both with
history of diabetes mellitus, and hyperkalemia was reported
as a TEAE by one subject. Of these, one TEAE each of
hyperglycemia and hyperkalemia were considered to be
possibly related to trial medication; excursions outside the
normal range have been reported in other trials.
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Figure 2 | Plots of individual tolvaptan pharmacokinetic
parameters versus baseline creatinine clearance (CrCL). AUCN,
area under the curve to infinity; CL/F, clearance; Cmax, maximum
plasma concentration; t1/2,z, terminal half-life.
Kidney International (2014) 85, 953–961 955
SE Shoaf et al.: Tolvaptan in subjects with renal impairment c l i n i ca l t r i a l
DISCUSSION
Following oral administration of a single 60-mg dose,
tolvaptan plasma concentrations were higher in the groups
with renal impairment (CrCL o30 and 30–60ml/min) than
in the group with preserved renal function group (CrCL
460ml/min). On analysis by linear regression, AUCN was
the only pharmacokinetic parameter to show a significant
relationship with baseline CrCL, with increasing AUCN
associated with decreasing baseline CrCL. The tolvaptan
Cmax increased slightly, and clearance decreased slightly with
decreasing baseline CrCL, but neither trend reached statis-
tical significance. Baseline CrCL was not correlated with
tolvaptan plasma protein binding and, therefore, changes in
parameters reflecting unbound tolvaptan (Cmax,u, AUCN,u,
and CL/Fu ) paralleled those for Cmax, AUCN, and CL/F
(Table 2).
The 60-mg dose used in this trial is the maximum dose for
the treatment of hyponatremia and is reached when 15- and
30-mg doses do not provide sufficient increases in serum
sodium. The pharmacokinetic parameters determined for
the group with preserved renal function were similar to
those previously reported for the 60-mg dose in the US
single ascending dose trial.10 In the present trial and the
earlier trial, mean Cmax values were 417 and 450ng/ml,
respectively; the corresponding mean AUCN values were
3.53 and 3.66mg h/ml, and mean CL/F values were 4.55 and
4.12ml/min/kg.
Tolvaptan Cmax and AUCN values did not correlate with
changes in any pharmacodynamic parameter after tolvaptan
dosing. This finding was not unexpected, given that exposure
to tolvaptan after a single 60-mg dose was sufficient to
produce a maximal increase in urine excretion rate in all
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Figure 3 |Mean urine excretion rate and free water clearance plotted at the end time of the collection interval at baseline and after
tolvaptan dosing.
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subjects.10 Baseline CrCL was, however, highly positively
correlated with changes in many of the pharmacodynamic
end points following tolvaptan administration: increases in
urine output and FWC were larger and returned to baseline
more rapidly than in subjects with renal impairment.
Clinically insignificant increases in mean urinary excretion
of osmoles, sodium, and potassium were evident in the 24-h
period after tolvaptan dosing for subjects with CrCL
460ml/min but not those with renal impairment. This
finding may reflect the more rapid rate of urine flow seen
after tolvaptan administration in the CrCL 460-ml/min
group, which may prevent the kidney from reabsorbing much
of the filtered electrolytes. However, from 24 to 48 h after
dosing, urinary electrolyte excretion dropped below baseline
levels as subjects with preserved renal function started to
recover electrolyte losses. In contrast, tolvaptan did not affect
urinary electrolytes in subjects with renal impairment likely
because they could not generate a high rate of urine flow.
Increases in FWC were observed in all subjects shortly after
dosing, with fractional FWC higher in subjects with lower
baseline CrCL.
Consistent with the larger and more rapid increases in
urine output and FWC, subjects with preserved renal
function had more rapid increases in serum osmolality and
serum sodium than did those with renal impairment.
Nevertheless, the overall magnitude of the changes from
baseline did not differ by CrCL. Thus, subjects with renal
impairment achieved the same maximum levels of serum
osmolality and serum sodium as did subjects with CrCL
460ml/min; however, these levels occurred at a later time
following tolvaptan dosing, consistent with the smaller
increases in urine output and FWC seen after tolvaptan
administration. In turn, the smaller increases in urine
output and FWC with decreasing CrCL are consistent with
a reduced number of functioning nephrons in subjects with
renal impairment.14 Urine output and FWC following the
single 60-mg dose of tolvaptan may, therefore, provide a
measure of the number of functioning nephrons or of renal
function in general. As the number of functioning nephrons
and CrCL decline, a longer duration is needed to excrete
sufficient water to affect an increase in serum sodium and
osmolality.
Tolvaptan administration produced a negative fluid
balance in each CrCL group on day 1, averaging 530ml in
the group with CrCL o30ml/min and B1850ml in the
other two groups. The negative fluid balance indicates that
subjects did not drink enough water during the first 24 h
following tolvaptan administration to recover the fluid lost.
It is interesting to note that subjects in the CrCL 460- and
30- to 60-ml/min groups had similar changes in fluid
Table 3 |Daily urine volume, fluid intake, and free water
clearance by CrCL group
Parametera
CrCL
o30ml/min
(N¼ 12)
CrCL
30–60ml/min
(N¼ 12)
CrCL
460ml/min
(N¼ 12)
Urine volume (ml)
Baseline, day 0 2099 (806) 1949 (586) 2644 (897)
0–24h after dosing 3189 (850) 4654 (1504) 6891 (1571)
Change from baseline 1090 (785) 2705 (1375) 4247 (1673)
24–48h after dosing 2636 (850) 2462 (1038) 2259 (1186)
Change from baseline 537 (732) 513 (789)  385 (755)
Fluid intake (ml)
Baseline, day 0 2254 (662) 2162 (374) 2332 (753)
0–24h after dosing 2815 (682) 2998 (578) 4726 (1182)
Change from baseline 560 (800) 836 (416) 2393 (1137)
24–48h after dosing 2555 (708) 2467 (574) 2628 (1315)
Change from baseline 300 (769) 304 (452) 296 (1031)
Free water clearance (ml/min)
Baseline, day 0 0.0 (0.5)  0.6 (0.5)  0.3 (0.7)
0–24h after dosing 0.9 (0.5) 1.3 (1.0) 2.4 (0.8)
Change from baseline 0.9 (0.6) 1.9 (0.9) 2.7 (1.0)
24–48h after dosing 0.5 (0.4)  0.3 (0.8)  0.3 (0.7)
Change from baseline 0.5 (0.5) 0.4 (0.4) 0.0 (0.6)
Abbreviation: CrCL, creatinine clearance.
aValues are mean (±s.d.).
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balance on day 1, meaning that subjects in the CrCL
460-ml/min group drank B1500ml more water. The fluid
balance observed in these subjects was also similar to
that observed in a US clinical trial in patients with
euvolemic or hypervolemic hyponatremia (serum creatinine
o3.5mg/dl) initially administered a 15-mg dose of tolvap-
tan, even though the mean urine output for this dose was
only 3218ml, compared with the higher urine volumes seen
in this trial (Table 3).2
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clearance group after tolvaptan dosing.
Table 4 |Cmax, maximum change from baseline, and tmax of
serum osmolality and sodium by CrCL group after tolvaptan
dosing
Parameter
CrCL o30
ml/min (N¼ 12)
CrCL 30–60
ml/min (N¼ 12)
CrCL 460
ml/min (N¼ 12)
Serum osmolality
Cmax (mOsm/kg)
a 324 (11) 315 (11) 304 (4)
Maximum change
from BLa
9 (4) 18 (8) 11 (4)
tmax (h)
b 36 (8–48) 30 (6–36) 8 (4–48)
Serum sodium
Cmax (mEq/l)
a 143 (4) 146 (2) 147 (2)
Maximum change
from BLa
5 (3) 6 (2) 6 (2)
tmax (h)
b 32 (2–48) 24 (4–36) 7 (2–36)
Abbreviations: BL, baseline; Cmax, maximum plasma concentration; CrCL, creatinine
clearance; tmax, time to Cmax.
aMean (±s.d.).
bMedian (range).
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Figure 8 |Mean (±s.d.) daily urinary excretion of osmoles,
sodium, and potassium at baseline, and change from baseline
after tolvaptan dosing.
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Results from this trial were similar to those seen in
autosomal dominant polycystic kidney disease patients.6
In this report on 20 subjects with autosomal dominant
polycystic kidney disease, with estimated CrCL by Cockcroft
and Gault,15 of 430ml/min and 10 subjects with 460ml/
min were administered tolvaptan as a split-dose regimen of
45mg on awakening and 15mgB8 h later for 7 days, and on
day 8, they underwent renal function testing following
administration of a 45-mg dose.6 For the time period of
testing, 2.0–3.5 h postdose tolvaptan plasma concentrations
would have been close to their peak as time to Cmax is B2 h
and thus sufficient to produce maximal increases in urine
output. Compared with testing at baseline, a statistically
significant reduction of 8.6% was observed in glomerular
filtration rate (as determined by iothalamate infusion) and
mean fractional FWC was significantly increased by 3.5%.
These results are similar to the CrCL and fractional FWC
changes observed after a single dose of tolvaptan and indicate
that the response to tolvaptan does not change greatly
following multiple doses.
Despite the increase in exposure to tolvaptan, subjects
with renal impairment had delayed pharmacodynamic
responses, including increases in serum osmolality and
serum sodium, compared with subjects with preserved
renal function. On the basis of these findings, no adjustment
to tolvaptan (Samsca) dosing for subjects with impaired
renal function is recommended in labeling. Individual
values of CrCL in the group with the greatest renal
impairment ranged from 15 to 31ml/min in this trial,
corresponding to stage 4 chronic kidney disease.16 The
effects of tolvaptan on serum sodium levels are likely lost
at very low levels of renal function and, therefore the use
of this agent in patients with CrCL o10ml/min is not
recommended.4
This trial has limitations. The group with CrCL 30–60
ml/min was not matched for age, race, and sex with the other
two groups, as such direct comparisons were not planned or
performed. Analysis between groups was addressed in the
linear regression analyses that used individual baseline CrCL
values. In addition, a formal sample size was not determined,
but the sample sizes of 12 subjects per group and 36 in total
for the pharmacokinetic and pharmacodynamic analyses
were consistent with other recent trials evaluating the impact
of renal impairment on a drug’s pharmacokinetics and
pharmacodynamics.17–19
In summary, increases in urine excretion rate and FWC
following tolvaptan administration were higher in subjects
with preserved renal function (greater number of intact
nephrons) than in those with renal impairment (smaller
number of intact nephrons); however, increases were
observed in all subjects. In addition, increased serum sodium
and serum osmolality were seen in all subjects. No
adjustment to tolvaptan (Samsca) dosing for subjects with
impaired renal function is recommended in labeling. The use
of tolvaptan in patients with CrCL o10ml/min is not
recommended.
MATERIALS AND METHODS
Subjects
Men and women agedX18 years, with a body mass indexp35kg/m2
and an anticipated CrCL of o30 or 30–60ml/min were evaluated
for 24-h CrCL at screening and were than allocated to the
appropriate group (12 subjects planned per group). Subjects were
recruited for the CrCL 460-ml/min group based on those enrolled
in the CrCLo30-ml/min group, matching for age, weight, and sex.
Eligible subjects were in stable health despite renal dysfunction
and agreed to remain abstinent or practice double-barrier forms
of contraception, if of childbearing potential. All subjects provided
written informed consent. Subjects with significant medical
abnormalities (other than renal impairment), prior renal transplant
or current dialysis, supine blood pressure 4160/95 or o95/
50mmHg, supine heart rate o40 or 490 beats per min, history
of drug or alcohol abuse, mental disorders, or significant bleeding,
or history or evidence of hepatitis or HIV were excluded.
Consumption of products or beverages containing methylxanthines,
grapefruit, or Seville oranges within 72 h, or use of prescription or
over-the-counter medications or supplements within 14 days, or
antibiotics within 30 days before dosing was not allowed.
Trial design
This single-dose, open-label, parallel-group trial was conducted at
two sites in the United States. Subjects were screened for eligibility
within 21 days before the trial, reported to the trial clinic on day
 1, and had baseline pharmacodynamic assessments on day 0.
Subjects received a single 60-mg oral dose of tolvaptan with 240ml
water on day 1 after fasting for X10 h. Water was withheld for 2 h
before and after dosing, but was otherwise allowed ad libitum.
Lunch was provided on day 1 after the 4-h postdose pharmacoki-
netic and pharmacodynamic assessments had been completed.
Pharmacokinetic and pharmacodynamic assessments were per-
formed at prespecified times for 48 h after dosing. Subjects were
discharged from the clinic on day 3 and then received a safety
follow-up telephone call on day 8 (ie, 7 days after dosing).
This trial was conducted in accordance with ethical principles
originating in the Declaration of Helsinki Principles, and in
compliance with Good Clinical Practices and national regulatory
guidelines. The protocol and informed consent form were approved
by the governing institutional review board or independent ethics
committee at each center before that site enrolled any subjects.
Assessments
Pharmacokinetics. Blood samples for determination of tol-
vaptan plasma concentrations were collected within 10min before
dosing, and then at 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 28, 32, 36, and 48 h
after dosing in tubes containing sodium heparin as anticoagulant.
An additional blood sample was collected within 30min before
dosing in a tube containing potassium-2 ethylene diamine
tetraacetic acid for determination of the plasma protein binding of
tolvaptan.
Pharmacodynamics. Blood samples for measurement of serum
osmolality, sodium and potassium ion, and creatinine were collected
within 30min before, and at 2, 4, 6, 8, 12, 24, 28, 32, 36, and 48 h
after dosing. Baseline samples were also collected on day 0 at times
corresponding to the predose and 12-h postdose samples scheduled
for day 1. Urine was collected and pooled for the intervals 0–4, 4–8,
8–12, and 12–24 h on days 0 (baseline), 1, and 2. Subjects were asked
to void immediately before blood sample collections at correspond-
Kidney International (2014) 85, 953–961 959
SE Shoaf et al.: Tolvaptan in subjects with renal impairment c l i n i ca l t r i a l
ing time points. Urine volume for each interval was recorded, and an
aliquot was taken for determination of urine osmolality, sodium,
potassium, and creatinine.
Safety. Adverse events were recorded from days  1 to 3
at the trial center and at a follow-up telephone call on day 8,
and were coded using the Medical Dictionary for Regulatory
Activities. Vital signs and 12-lead electrocardiograms were collected
at check-in, on days 0 and 1, and at discharge. Clinical laboratory
tests and physical examinations were conducted at check-in and
discharge.
Bioanalytics
Tolvaptan plasma concentrations were measured at Prevalere Life
Sciences (Whitesboro, NY) using a high-performance liquid chrom-
atography with tandem mass spectrometric detection method that
had been validated over the concentration range of 5–1000 ng/ml.10
For determination of plasma protein binding, plasma samples were
dialyzed for 7 h at 37 1C using a rapid equilibrium dialysis 96-well
system at Covance Laboratories (Madison, WI), and then aliquots of
the plasma and dialysate were analyzed by high-performance liquid
chromatography with tandem mass spectrometry to allow
calculation of %fu.
Pharmacokinetic analysis
For each subject, tolvaptan plasma–concentration–time data were
analyzed using non-compartmental methods, with the actual blood
sampling time used for pharmacokinetic calculations. Values for
Cmax and time to Cmax were determined directly from the observed
data, AUC from time 0 to the last sampling time was estimated
using the linear trapezoidal rule, and other parameters were
calculated using standard methods.20 Pharmacokinetic parameters
for unbound tolvaptan were determined by multiplying the
corresponding parameter by %fu. All pharmacokinetic calculations
were performed with WinNonlinPro version 5.2 (Pharsight,
Mountain View, CA).
Pharmacodynamic analysis
CrCL was calculated from the ratio of urine/serum creatinine
concentration multiplied by urine flow rate. FWC was calculated
from urine flow rate minus the product of the urine/plasma
osmolality ratio and urine flow rate. Fluid intake was determined
from all liquids consumed orally, including the 240ml of water used
for tolvaptan administration and any foods containing significant
amounts of water. Fluid balance represented the difference between
fluid intake and urine output. Calculations were performed using
SAS version 9.2 (SAS Institute, Cary, NC). Fractional FWC was
determined as the ratio of FWC to CrCL using Excel (Microsoft
Professional Plus 2010; Microsoft, Seattle WA).
Pharmacokinetic/pharmacodynamic correlations
Potential associations between pharmacokinetic and pharmacody-
namic parameters were explored graphically and by linear regression
using Sigma Plot version 10 (SPSS Institute, Chicago, IL). Individual
tolvaptan Cmax and AUCN values were compared with individual
percent changes from baseline in CrCL, and changes from baseline
in 24-h urine volume and FWC. In addition, individual baseline
CrCL values were compared with tolvaptan pharmacokinetic
parameters, and changes from baseline in serum and urine
pharmacodynamic parameters.
Statistics
No formal sample size determination was carried out to determine
the statistical power of this trial. The pharmacokinetic parameters
were summarized by CrCL group in subjects with valid tolvaptan
plasma measurements using descriptive statistics determined by
S-Plus version 6.1 (Insightful, Seattle, WA). The pharmacodynamic
parameters were similarly summarized using SAS version 9.2 (SAS
Institute), except for fractional FWC, which was summarized using
Excel.
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